Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cytokinetics, Incorporated - Common Stock (NQ:CYTK)

33.68 -0.98 (-2.83%)
Streaming Delayed Price Updated: 12:03 PM EDT, Jul 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cytokinetics, Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Cytokinetics Sets Stage For Mid-Stage Study For Heart Failure Drug After Encouraging Data From Phase 1 Study
Cytokinetics presented positive Phase 1 trial data for CK-586, a potential heart failure treatment, showing safety, tolerability, and dose-linearity. Phase 2 trial expected to start Q4 2024. 
Via Benzinga
CYTK Stock Earnings: Cytokinetics Misses EPS, Misses Revenue for Q2 2024
CYTK stock results show that Cytokinetics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Cytokinetics' Wild Ride: Can Investors Forgive The Royalty Pharma Deal?
CEO Robert Blum says there are key components to the funding arrangement with Royalty Pharma that investors are missing. 
Via Investor's Business Daily
7 Biotech Stocks to Boost Your Portfolio to Peak Health
With biotech stocks commanding a permanently relevant narrative, you can’t afford to ignore these highly endorsed ideas. 
Via InvestorPlace
Peering Into Cytokinetics's Recent Short Interest
Via Benzinga
June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge
Biotech surge alert! Discover three biotech stocks to buy as they catch up with the market in the rest of 2024. 
Via InvestorPlace
(CYTK) - Analyzing Cytokinetics's Short Interest
Via Benzinga
$100 Invested In Cytokinetics 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Dow Dips Over 550 Points; BJ's Wholesale Club Earnings Beat Views
Via Benzinga
Topics Earnings Stocks
Heart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts Observe
Unlock the latest on Royalty Pharma plc & Cytokinetics Inc.'s strategic funding collaboration for aficamten's commercialization and cardiovascular pipeline expansion. 
Via Benzinga
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Stocks Mixed Amid Flood Of Economic Data
The Nasdaq is up triple digits midday, trading at fresh record highs thanks to Nvidia's post-earnings pop. 
Via Talk Markets
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
2 Incredible Growth Stocks to Buy Right Now
These two biotech stocks could be big winners in the years ahead. 
Via The Motley Fool
Here's How Much $100 Invested In Cytokinetics 10 Years Ago Would Be Worth Today
Via Benzinga
Gold Falls Sharply; US Composite PMI Surges In May
Via Benzinga
Why Cytokinetics (CYTK) Shares Are Falling
Cytokinetics shares are trading lower by 15.8% during Thursday's session. The company announced the pricing of a public offering of 9,803,922 shares. 
Via Benzinga
Why NVIDIA Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
NVIDIA To Rally Over 39%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
VF Corp Posts Weak Q4 Results, Joins NetEase, Cytokinetics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
From Royalty Pharma plc; Cytokinetics
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Cytokinetics Reveals More From The Study That Boosted Shares 83% In A Day
The company is hoping to take on Bristol Myers Squibb's Camzyos, a treatment for obstructive HCM. 
Via Investor's Business Daily
CYTK Stock Earnings: Cytokinetics Misses EPS, Misses Revenue for Q1 2024
CYTK stock results show that Cytokinetics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
Investors concerned about broader market undulations may want to consider the resilience narrative of these biotech stocks to buy. 
Via InvestorPlace
3 Biotech Stocks to Buy on the Dip: April 2024
With medical innovation being a resilient space, investors can have confidence with these biotech stocks to buy on the dip. 
Via InvestorPlace
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas. 
Via InvestorPlace
Masters In Trading - Saturday, March 16
In this snippet from Friday's trading session, I review my various trades from the past week. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.